Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

25 Mortarini R, Borri A, Tragni G, Bersani
I,Vegetti C, Bajetta E, Pilotti S,
Cerundolo V, Anichini A. Peripheral
burst of tumor-specific cytotoxic T lymphocytes
and infiltration of metastatic
lesions by memory CD8 + T cells in melanoma
patients receiving interleukin
12. Cancer Res 2000; 60: 3559±68.
26 Lee PP,Yee C, Savage PA, Fong L,
Brockstedt D,Weber JS, Johnson D,
Swetter S, Thompson J, Greenberg
PD, Roederer M, Davis MM.
Characterization of circulating T cells
specific for tumor-associated antigens
in melanoma patients. Nat Med 1999;
5: 677±85.
27 Molldrem JJ, Lee PP,Wang C, Felio K,
Kantarjian HM, Champlin RE,
Davis MM. Evidence that specific T
lymphocytes may participate in the
elimination of chronic myelogenous
leukemia. Nat Med 2000; 6: 1018±23.
28 Valmori D, Dutoit V, Lienard D, Rimoldi
D, Pittet MJ, Champagne P,
Ellefsen K, Sahin U, Speiser D,
Lejeune F, Cerottini JC, Romero P.
Naturally occurring human lymphocyte
antigen-A2 restricted CD8 + T-cell response
to the cancer testis antigen NY-
ESO-1 in melanoma patients. Cancer
Res 2000; 60: 4499±506.
29 Pittet MJ,Valmori D, Dunbar PR,
Speiser DE, Lienard D, Lejeune F,
Fleischhauer K, Cerundolo V, Cerottini
JC, Romero P. High frequencies
of naive Melan-A/MART-1-specific
CD8 + T cells in a large proportion of human
histocompatibility leukocyte antigen
(HLA)-A2 individuals. J Exp Med
1999; 190: 705±15.
30 Lamouse-Smith E, Clements VK, Ostrand-Rosenberg
S. Beta 2M ±/±
knockout mice contain low levels of
CD8 + cytotoxic T lymphocyte that mediate
specific tumor rejection. J Immunol
1993; 151: 6283±90.
31 Darrow TL, Slingluff CL Jr, Seigler
HF. The role of HLA class I antigens
in recognition of melanoma cells
by tumor-specific cytotoxic T lymphocytes.
Evidence for shared tumor antigens.
J Immunol 1989; 142: 3329±35.
32 Crowley NJ, Darrow TL, Quinn-
Allen MA, Seigler HF. MHC-re-
References
stricted recognition of autologous melanoma
by tumor-specific cytotoxic T
cells. Evidence for restriction by a dominant
HLA-A allele. J Immunol 1991;
146: 1692±9.
33 Van Pel A,Warnier G,Van den
Eynde B, Lethe B, Lurquin C, Boon T.
Tum ± antigens, TSTA, and T cell immune
surveillance. Ann NY Acad Sci
1991; 636: 43±51.
34 van der Bruggen P, Traversari C,
Chomez P, Lurquin C, De Plaen E,
Van den Eynde B, Knuth A, Boon T.
A gene encoding an antigen recognized
by cytolytic T lymphocytes on a human
melanoma. Science 1991; 254: 643±7.
35 Walden P. Hybrid cell vaccination for
cancer immunotherapy. Adv Exp Med
Biol 2000; 465: 347±54.
36 de Vries JE, Spits H. Cloned human
cytotoxic T lymphocyte (CTL) lines reactive
with autologous melanoma cells. I.
In vitro generation, isolation, and analysis
to phenotype and specificity. JImmunol
1984; 132: 510±9.
37 Van den Eynde BJ, Boon T. Tumor
antigens recognized by T lymphocytes.
Int J Clin Lab Res 1997; 27: 81±6.
38 Renkvist N, Castelli C, Robbins PF,
Parmiani G. A listing of human tumor
antigens recognized by T cells. Cancer
Immunol Immunother 2001; 50: 3±15.
39 Brichard V,Van Pel A,Wolfel T, Wolfel
C, De Plaen E, Lethe B, Coulie P,
Boon T. The tyrosinase gene codes for
an antigen recognized by autologous cytolytic
T lymphocytes on HLA-A2 melanomas.
J Exp Med 1993; 178: 489±95.
40 Kawakami Y, Eliyahu S, Delgado CH,
Robbins PF, Sakaguchi K, Appella E,
Yannelli JR, Adema GJ, Miki T, Rosenberg
SA. Identification of a human
melanoma antigen recognized by tumor-infiltrating
lymphocytes associated
with in vivo tumor rejection. Proc Natl
Acad Sci USA 1994; 91: 6458±62.
41 Kawakami Y, Eliyahu S, Sakaguchi K,
Robbins PF, Rivoltini L,Yannelli JR,
Appella E, Rosenberg SA. Identification
of the immunodominant peptides
of the MART-1 human melanoma antigen
recognized by the majority of HLA-
A2-restricted tumor infiltrating lymphocytes.
J Exp Med 1994; 180: 347±52.
243